CDC28 protein kinase regulatory subunit 1B pseudogene 6Genealiases: []
Q-omics provides the consensus-scored CKS1BP6 profile across patient tissues and cancer cell-line models. CKS1BP6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CKS1BP6 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, CKS1BP6 RNA expression shows 6,435 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, STAD, and UCEC as cancer lineages where CKS1BP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKS1BP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKS1BP6 survival associations across molecular data types. CKS1BP6 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKS1BP6 RNA expression–survival associations across cancer types. High CKS1BP6 expression shows unfavorable associations in ACC, KICH, DLBC, CHOL and PCPG, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CKS1BP6 RNA expression.
This table summarizes CKS1BP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CKS1BP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKS1BP6 shows higher tumor expression in STAD, COAD, READ, HNSC, LIHC and LUSC. The STAD box plot shows higher CKS1BP6 RNA expression in tumor versus normal tissue (log2 FC = +0.228, t-test p = .001).
This table shows molecular features associated with CKS1BP6 in patient tissues and cancer cell lines. In patient samples, CKS1BP6 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
